## **Core Concept**
Rituximab is a monoclonal antibody used in the treatment of certain cancers, such as non-Hodgkin's lymphoma, and autoimmune diseases. The nomenclature of monoclonal antibodies is crucial for understanding their origins and targets. The suffix and prefix of these antibodies provide information about their source and target.

## **Why the Correct Answer is Right**
The "-xi-" in Rituximab is part of the nomenclature system for monoclonal antibodies. According to this system, the part of the name between the prefix and the suffix often indicates the source or the specific target of the antibody. In the case of Rituximab, the prefix "Rituxi" can be broken down: "Rit" likely refers to the target (CD20), and "xi" denotes that it is a chimeric antibody. Chimeric antibodies contain parts from two different species, typically mouse and human.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not accurately reflect the meaning of the "-xi-" in Rituximab's name. Without specifying what A represents, it's hard to directly refute, but given the context, it's not relevant to the chimeric origin.
- **Option B:** Similarly, this option lacks context but is incorrect because it does not correctly represent the significance of "-xi-" in monoclonal antibody nomenclature.
- **Option D:** This option is incorrect for the same reasons as A and B; it does not accurately describe the meaning of "-xi-" in Rituximab.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that monoclonal antibodies ending with "-xi-" are chimeric, meaning they are composed of human and non-human (usually mouse) parts. Rituximab, being a chimeric monoclonal antibody, targets the CD20 antigen found on the surface of B cells, leading to B cell depletion.

## **Correct Answer:** B. chimeric.